GSA Capital Partners’s Tourmaline Bio TRML Stock Holding History

GSA Capital Partners’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,198	Closed	-$207K	–	2080
2024 Q4	$207K	Buy	+10,198	New	+$257K	0.02%	1399

Other funds holding TRML

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

GSA Capital Partners's TRML Position: Q1 2025 in Review

GSA Capital Partners sold out of Tourmaline Bio (TRML) in Q1 2025, closing a stake of 10,198 shares — an estimated $207K sold.

GSA Capital Partners first reported a position in TRML in Q4 2024 and held it in 1 quarter. The position peaked at $207K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRML as of Q1 2025.

GSA Capital Partners reported no remaining Tourmaline Bio position as of Q1 2025 after selling out during the quarter.
GSA Capital Partners sold 10,198 Tourmaline Bio shares in Q1 2025, an estimated $207K.
GSA Capital Partners first reported a position in Tourmaline Bio in Q4 2024 and held it in 1 quarter.
GSA Capital Partners's Tourmaline Bio position peaked at $207K in Q4 2024.
107 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.